Empagliflozin vs Dapagliflozin in Heart Failure: a Target Trial Emulation
Although this study cannot exclude lower short- and long-term risks of rehospitalization due to HF among patients with heart failure who initiate empagliflozin compared with dapagliflozin, no substantial difference was observed in the risks of all-cause death.
Authors
- Issa J Dahabreh (ORCID: https://orcid.org/0000-0002-2215-9931)
- Timothy L. Lash (ORCID: https://orcid.org/0000-0002-5240-5195)
- Kasper Bonnesen (ORCID: https://orcid.org/0000-0002-8626-2372)
- Uffe Heide‐Jørgensen (ORCID: https://orcid.org/0000-0002-8407-4618)
- Morten Schmidt
Institutions
- Emory University (US)
- Aarhus University Hospital (DK)
- Deaconess Hospital (US)
Publication Details
- Journal
- Journal of Cardiac Failure
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.cardfail.2025.11.495
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00